Flipkart allocates $100M internal fund to boost early stage start-ups

Flipkart allocates $100M internal fund to boost early stage start-ups

Published: 16 hours ago By Saif Ali Bepari

Indian origin ecommerce giant Flipkart to focus on investing in various startups including fintech, supply chain and SaaS   The estimated fund size has been capped at $60M - $100M   The company intends to obtain a 20-25% sta....

Netmeds acquires health tech start-up KiViHealth for $10 million

The acquisition will help Netmeds to increase its market value against rivals like 1mg, mChemist, Pharmeasy, Lybrate and more. Chennai-based online pharmaceutical portal Netmeds, has acquired Ahmedabad-based healthcare startup KiViHe....

CVS to sell CBD-infused topical products in 800 stores across 8 states

CVS has partnered with cannabis producers to infuse CBD and sell topical products like roll-ons, lotions, creams, slaves and sprays. CVS pharmacy has announced that it would sell hemp-derived CBD products, or products with cannabidiol, whi....

BeatO raises INR 11-75 Crore in pre-Series A round of funding

Apart from Orios Venture Partners, BeatO’s existing investors, Leo Capital & Blume Ventures also participated in the pre-Series A funding round. The proceeds from the funding round would be utilized to further expand the compan....

Roche’s Tecentriq immunotherapy for SCLC treatment approved by USDFA

The US FDA (Food & Drug Administration) has reportedly granted approval for Swiss drug-maker Roche Holding’s immunotherapy Tecentriq intended for treating ES-SCLC (Extensive Stage-Small Cell Lung Cancer). Reportedly, this is the l....

Marks and Spencer plans to launch supermarket-size food stores

The announcement ties in with a recent agreement signed by M&S with Ocado Marks and Spencer (M&S) is reportedly set to persuade families by opening super market-sized food stores to widen the range of food it offers. As per trusted....

PhaseBios Phase 1 PB2452 clinical trial results published in the NEJM

PhaseBio Biopharmaceuticals Inc., a U.S.-based clinical-stage biopharmaceutical company, has reportedly announced that results of its Phase 1 clinical trial  of PB2452, which is a new reversal agent for the anti-platelet drug ‘ti....

Industry Updates